HIV/AIDS Newsroom: July 2007

Browse the
Newsroom archive:

Microbicide Candidate Ushercell Not Effective in Preventing HIV (July 27, 2007)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Blood Test Predicts Dangerous Reaction to Abacavir (July 27, 2007)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Abstinence-Only Sex Education Fails to Reduce HIV Risk in High-Income Countries (July 26, 2007)
In British Medical Journal
HIV Patients Likely to Get Potentially Fatal Brain Diseases (July 26, 2007)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
HIV Patients Live Longer, Face Greater Risks (July 26, 2007)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Clinical Data Show Pfizer's Antiretroviral Maraviroc Reduces HIV Viral Loads Among Treatment-Naive People, Company Says (July 26, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Darunavir Matches, and in Some Patients Outperforms, Lopinavir/Ritonavir as Second-Line and Third-Line Treatment (July 25, 2007)
For the first time, a drug has been found that matches the potency of lopinavir/ritonavir in second-line and third-line patients, and which might potentially even outperform lopinavir/ritonavir in certain numbers of those patients. All without compromising safety and tolerability, and apparently without paying resistance consequences if virologic failure occurs. Edwin DeJesus, M.D., reports.
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from TheBodyPRO.com
Tenofovir-Containing Regimens May Not Be the Best Option for Patients With Abnormal Baseline Renal Function (July 25, 2007)
Tenofovir-containing regimens may not be the best option for patients who already have an abnormal baseline renal function; however, for patients with an otherwise normal baseline renal function, who are not taking nephrotoxic agents or who do not have significant comorbid conditions that predispose them to renal insufficiency, routine renal monitoring, as we do for many other patients, should suffice before prescribing tenofovir.
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from TheBodyPRO.com
Maraviroc Underperforms Efavirenz in Treatment-Naive Study (July 25, 2007)
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from TheBodyPRO.com
Can HLA-B*5701 Testing Help Avoid Abacavir Hypersensitivity Reaction? (July 25, 2007)
Avoiding abacavir hypersensitivity reaction may be as easy as screening for the HLA-B*5701 allele in any HIV-infected, abacavir-naive patient for whom abacavir therapy is being considered. Graeme Moyle, M.D., reports.
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from TheBodyPRO.com

VIEW ALL ARTICLES

MOST VIEWED ARTICLES

	HIV Management Today: Mental Health & HIV, the Uncharted Territory
	10 Top Studies Whose Impact Will Last Well Beyond CROI 2013
	CROI 2013: Women's Issues in HIV Research (Video)
	Danish Study Targets HIV Reservoir, in Latest Search for HIV Cure
	PrEP Failures and Successes: One Study Whose Impact Will Last Well Beyond CROI 2013
	HIV Opportunistic Infection Guidelines Updated

More Most Viewed Articles

TheBodyPRO.com is a service of Remedy Health Media, LLC, 500 5th Avenue, 19th Floor, New York, NY 10110. TheBodyPRO.com and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of TheBodyPRO.com's homepage, topic pages, page designs and HTML code. General Disclaimer: TheBodyPRO.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBodyPRO.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.